Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 137.94M | 135.16M | 91.37M | 53.91M | 200.58M | 853.00K |
Gross Profit | 79.51M | 131.57M | -129.20M | 47.16M | 118.29M | -74.03M |
EBITDA | -137.94M | -154.56M | -190.11M | -131.56M | 71.97M | -111.22M |
Net Income | -110.27M | -122.31M | -147.03M | -116.95M | 66.97M | -111.14M |
Balance Sheet | ||||||
Total Assets | 495.34M | 547.11M | 696.38M | 758.03M | 609.37M | 332.98M |
Cash, Cash Equivalents and Short-Term Investments | 417.94M | 471.39M | 618.83M | 710.41M | 579.09M | 295.38M |
Total Debt | 10.20M | 10.84M | 11.84M | 6.47M | 12.33M | 17.84M |
Total Liabilities | 57.66M | 60.18M | 135.02M | 135.99M | 143.32M | 148.97M |
Stockholders Equity | 437.68M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M |
Cash Flow | ||||||
Free Cash Flow | -130.37M | -150.35M | -136.72M | -109.28M | 92.03M | -80.56M |
Operating Cash Flow | -130.36M | -150.05M | -133.91M | -108.82M | 92.61M | -80.36M |
Investing Cash Flow | -237.00K | -298.00K | -2.77M | -464.00K | -575.00K | -196.00K |
Financing Cash Flow | 670.00K | 1.55M | 45.10M | 241.46M | 190.33M | 215.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
51 Neutral | $346.38M | ― | -23.46% | ― | 54.55% | 36.41% | |
50 Neutral | $769.19M | ― | -69.21% | ― | -13.76% | 57.73% | |
48 Neutral | $492.46M | ― | 34.94% | ― | ― | ― | |
45 Neutral | $595.59M | ― | -150.50% | ― | ― | -18.75% | |
42 Neutral | $724.62M | ― | -62.58% | ― | ― | 4.28% | |
40 Underperform | $312.44M | ― | -60.45% | ― | ― | 6.99% |
On June 18, 2025, Prothena Corporation plc announced a significant reduction in its workforce by approximately 63% to cut operating costs and focus on its remaining wholly-owned programs and business development activities. This decision follows the company’s earlier announcement on May 23, 2025, to discontinue the development of birtamimab. The workforce reduction is expected to be completed by the end of the fourth quarter of 2025, with affected employees receiving severance packages. The company anticipates recognizing $16 to $20 million in severance and related benefits expenses. Additionally, the employment of Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford will terminate on August 1, 2025, as part of this reduction, triggering severance benefits and stock option adjustments.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
On June 15, 2025, Prothena Corporation announced that its partner Roche will advance prasinezumab into Phase III development for early-stage Parkinson’s disease. This decision follows data from the Phase IIb PADOVA study and ongoing open-label extensions, which suggest potential clinical benefits of prasinezumab, a first-in-class anti-alpha-synuclein antibody. The studies indicated positive trends towards reduced motor progression and provided biomarker evidence of prasinezumab’s impact on disease biology. This advancement could position prasinezumab as a potential disease-modifying treatment for Parkinson’s, addressing a significant unmet need for over 10 million affected individuals globally.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
On May 23, 2025, Prothena Corporation announced that its Phase 3 AFFIRM-AL clinical trial for birtamimab in AL amyloidosis patients did not meet its primary or secondary endpoints, leading to the discontinuation of birtamimab’s development. As a result, Prothena plans to reduce operating expenses, including a significant workforce reduction, and will provide further updates in June. Despite the setback, Prothena remains focused on its other pipeline projects, including upcoming data from the Phase 1 ASCENT trials on PRX012 in Alzheimer’s disease and updates from its partners.
The most recent analyst rating on (PRTA) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
On May 13, 2025, Prothena Corporation plc held its annual general meeting where shareholders approved an amendment to the 2018 Long Term Incentive Plan, increasing the number of shares authorized for issuance by 2,000,000. Additionally, shareholders re-elected board members, ratified the appointment of KPMG LLP as the independent auditor for 2025, and approved executive compensation.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.